Claim OwnershipHeart Matters
Subscribed: 93Played: 646
Subscribe
© Copyright 2024 ReachMD. All rights reserved.
Description
Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and more.
So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.
So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.
185 Episodes
Reverse
Host: Javed Butler, MD, MBA, MPH
Guest: Jeffrey Wilson, MD
There’s a decent amount of evidence showing allergic immune responses could have connections with heart disease. But with the knowledge gaps that exist, a need for bigger cohorts is necessary to get more information and data. So to explore the link between allergic reactions from food and heart disease, Dr. Javed Butler is joined by Dr. Jeffrey Wilson, Allergist and Immunologist in the Department of Medicine’s Division of Asthma, Allergy, and Immunology at the University of Virginia.
Host: Javed Butler, MD, MBA, MPH
Guest: Michael J. LaMonte, PhD, MPH
The American Heart Association recommends physical activity to help lower the risk of heart failure, but how much exercise is needed, especially for older women, to lower that risk? According to a recent study, even just low-intensity exercise for 30 minutes is associated with a 25 percent lower risk of overall heart failure. Dive further into the findings with Dr. Javed Butler and Dr. Michael LaMonte, a Research Professor of Epidemiology and Environmental Health at the University of Buffalo.
Host: Javed Butler, MD, MBA, MPH
Guest: Chiadi Ndumele, M.D., Ph.D., M.H.S.
For the first time, the American Heart Association (AHA) has identified cardiovascular-kidney-metabolic (CKM) syndrome, which reflects a strong overlap between heart disease, kidney disease, and obesity. The major clinical consequence of CKM syndrome is multi-organ dysfunction with a particularly high incidence and burden of cardiovascular disease (CVD), and the result of this is premature morbidity and mortality. So as a result, recognizing CKM syndrome is the first step in earlier diagnosis and treatment. Dive into this episode with Dr. Javed Butler who’s joined by Dr. Chiadi Ndumele, Associate Professor of Medicine and the Director of Obesity and Cardiometabolic Research at Johns Hopkins University.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Dave L. Dixon, PharmD, FACC, FCCP, FNLA, BCPS, BCACP, CDE, CLS
What would the cost-effectiveness look like if the uptake of a pharmacist-prescribing model for hypertension were to be put into practice? A new study shows that a pharmacist-prescribing method could have significant economic impact on the U.S. healthcare system. Dive in with Dr. Mary Katherine Cheeley as she speaks with Dr. Dave Dixon, Nancy L. and Ronald H. McFarlane Professor of Pharmacy at Virginia Commonwealth University School of Pharmacy, to discuss the findings from the study, titled “Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States,” which was published in JAMA Network.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Javed Butler, MD, MBA, MPH
There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through the study’s key findings with Dr. Mary Katherine Cheeley is fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD
The risk of cardiovascular disease is twice as great among patients living with HIV, and this could partly be due to traditional risk factors, along with nontraditional risk factors. Here to discuss the results from the REPRIEVE study with Dr. Mary Katherine Cheeley is Dr. Steve Grinspoon, Co-Principal Investigator and Professor of Medicine at Harvard Medical School in Boston.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA
The National Lipid Association (NLA) recently published updated recommendations for lifestyle therapies to manage three common dyslipidemias in adults. To discuss this, Dr. Mary Katherine Cheeley is joined by Dr. Carol Kirkpatrick, Clinical Lipid Specialist and Clinical Scientist at Midwest Biomedical Research.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD
Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Maya S. Safarova, MD, PhD, FNLA
Learn which patients with low-density lipoprotein (LDL) would benefit from this group of medication. In this episode, Dr. Alan Brown is joined by Dr. Maya Safarova, Chief Fellow in the Department of Cardiovascular Medicine at the University of Kansas Medical Center, to discuss the benefits of non-statin LDL lowering therapies.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Alan S. Brown, MD, FACC, FAHA, FNLA
Both clinical trials for lowering Lp(a) had patients with established atherosclerotic cardiovascular disease (ASCVD). Join in for a further discussion on important updates presented at the 2023 National Lipid Association Meeting with Dr. Mary Katherine Cheeley and fellow ReachMD host, Dr. Alan Brown, Past President of the National Lipid Association.
Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623
Guest: Santica Marcovina, PhD, ScD
Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623
It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis. Sponsored by Novartis Pharmaceuticals Corporation. 6/23 278623
Host: Javed Butler, MD, MBA, MPH
Guest: John W. MacArthur
With many barriers standing in the way of people in the United States who need a heart transplant, fewer than 10 percent of patients actually receive this life-saving surgery according to Stanford Medicine. Therefore, surgeons are working on different techniques to increase the pool of healthy donated hearts. To speak more about this, Dr. Javed Butler is joined by Dr. John MacArthur, Assistant Professor of Cardiothoracic Surgery at Stanford School of Medicine.
Host: Javed Butler, MD, MBA, MPH
Guest: Pedro A Villablanca Spinetto, MD
A complex condition known as tricuspid valve regurgitation may cause concern for patients as it typically doesn’t show signs or symptoms until the disease is severe. So what technologies and therapies do we have to look forward to? Join Dr. Javed Butler as he speaks with Dr. Pedro Villablanca, Structural Heart Interventional Cardiologist at Henry Ford Health.
Guest: Patricia A. Pellikka, M.D.
Artificial intelligence (AI) has several applications in cardiology, such as echocardiography. Can machine learning and AI algorithms in echocardiology help clinicians better detect heart failure with preserved ejection fraction (HFpEF)? Dr. Patricia A. Pellikka, Director of the Ultrasound Research Center at the Mayo Clinic, shares data from ACC.23 and explores the potential of AI in detecting HFpEF.
Guest: Paul Sorajja, MD
TRILUMINATE was the first trial to take a look at the impact of tricuspid regurgitation (TR) reduction on patients, and its results may lead to significant improvements in care and quality of life. To learn more about this trial, Dr. Paul Sorajja from the Minneapolis Heart Institute Foundation details the key findings from this trial and explores their impact.
Guest: Ana Barac, MD, PhD
The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.
Host: Javed Butler, MD, MBA, MPH
Guest: Ana Barac, MD, PhD
Cardio-oncology is a novel field in cardiovascular medicine that has rapidly grown over the past few years. What kind of role does multidisciplinary care have in it? Dr. Javed Butler is joined by Dr. Ana Barac from the Inova Heart and Vascular Institute to take a look at where cardio-oncology is and where it could be headed.
Host: Marius M. Hoeper, MD
A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of this trial and explores how they may impact patients with PAH.
Comments
Download from Google Play
Download from App Store
United States